CITCCA data demonstrate more than 40% of high-risk stage I–III colorectal patients harbor molecular residual disease at clinical landmark, detectable only with ultrasensitive ctDNA testingMORRISVILLE, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback